Millions of children in developing countries like Kenya will soon be protected against typhoid fever, following an approval by Gavi to support the introduction of a vaccine. The funds that are up to the tune of Sh8.7 billion ($85 million) agreed by Gavi Alliance (formerly the Global Alliance for Vaccines and Immunisation) last week will go towards bulk-buying of new typhoid conjugate vaccines (TCVs), the alliance said yesterday.
“Typhoid has long been eliminated from most industrialised nations, but it is still a serious threat in developing countries where the vast majority of deaths occur,” said Dr Ngozi Okonjo-Iweala, Gavi board chair. Typhoid shots from five other drug makers, including one developed by privately-held Bharat Biotech, are also under development and expected to be available between 2018 and 2022. Gavi, which is backed by the Bill & Melinda Gates Foundation, the World Health Organisation, the World Bank, Unicef and donor governments, among others, funds bulk-buy vaccination programmes for poorer nations that can’t afford shots at developed-economy prices.

No Comments

Leave a Comment